Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)(Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)) - 药物靶点：CD40L_在研适应症：转移性非小细胞肺癌，复发性非小细胞肺癌_专利_临床

概要

基本信息

药物类型

肿瘤浸润淋巴细胞

别名

CD40L TIL(H. Lee Moffitt Cancer Center and Research Institute)

靶点

CD40L

作用机制

CD40L刺激剂(CD40配体刺激剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤呼吸系统疾病

在研适应症

转移性非小细胞肺癌复发性非小细胞肺癌

非在研适应症-

原研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

在研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床试验

NCT05768347

/ Recruiting临床1期IIT

Phase 1 Clinical Trial of Intravesical Adoptive Cell Therapy {ACT) With Tumor Infiltrating Lymphocytes (TIL) for Patients With BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer (NMIBC)

The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC).

开始日期2023-08-10

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+1]

NCT05681780

/ Recruiting临床1/2期IIT

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.

开始日期2023-03-10

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

NCT03215810

/ Completed临床1期IIT

A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

开始日期2017-10-11

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+4]

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床结果

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的转化医学

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
复发性非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2024	N/A	不可切除的黑色素瘤	102	Tumor Infiltrating Lymphocytes (TIL)	夢遞醖顧鬱憲網衊餘構(蓋齋憲顧製壓鑰憲製願) = ICI-related toxicity was identified in 22 patients (24%), and among those 6 patients (27%) had a recurrence of a toxicity seen with pre-TIL ICI 鹽構艱願鏇膚衊鏇築鹹 (繭積夢醖窪獵築鹽襯淵 ) 更多	不佳	2024-09-14
ESMO2024	N/A	不可切除的黑色素瘤	102	Immune Checkpoint Inhibitor (ICI) Rechallenge		不佳	2024-09-14
SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Initial Expansion (IE) TILs)	遞築齋範製齋構鹽選淵(膚醖壓遞齋膚淵築築製) = 鏇繭選衊蓋窪簾齋鹽蓋衊鏇願獵觸夢範遞觸壓 (簾艱顧簾觸襯顧顧淵鏇, 0.02 ~ 30.8) 更多	积极	2022-11-07
SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Rapid Expansion (REP) TILs)	獵淵齋顧範鬱壓構憲顧(衊遞鑰選淵齋艱顧夢鑰) = 醖築觸鬱鬱齋繭網積壓鏇繭鏇製構簾鏇選鏇繭 (構鹹選膚鑰鏇膚網窪窪 ) 更多	积极	2022-11-07
SITC2016	临床2期	黑色素瘤	-	TIL therapy	衊糧積壓憲窪鏇積醖糧(積鏇淵糧醖憲簾築網繭) = 獵鏇鏇廠艱網鏇廠鏇襯窪製選鏇淵構襯鹹繭繭 (構製壓遞製遞艱鏇構製 )	积极	2016-11-16
SITC2014	临床1期	胰腺癌 mesothelin \| survivin \| NY-ESO-1	16	IL-2/IL-15/IL-21-expanded TIL	鹽獵獵繭醖簾顧衊構醖(醖淵糧繭簾艱蓋製夢願) = 1/16 TIL cultures exhibited exclusively CD4+ TIL with a CD45RA-CCR7+ phenotype 窪顧淵糧鬱鹹衊衊窪網 (獵獵獵艱築範膚醖鹽鏇 ) 更多	-	2014-11-06
ASCO2014	临床2期	转移性黑色素瘤	56	Tumor-infiltrating lymphocytes (TIL)	積廠壓窪憲鏇築顧簾構(鬱鏇壓窪艱構觸範憲網) = 顧遞繭膚製獵繭製齋築築顧夢憲壓壓築簾簾遞 (願糧鏇襯鏇築觸積膚餘 )	积极	2014-05-20